

# Registration is now live for the 15th Annual Advances and Progress in Drug Design

*15th Annual Advances and Progress in Drug Design conference will be taking place on the 15–16 February 2016 at the Holiday Inn Kensington Forum Hotel in London*

LONDON, UNITED KINGDOM, October 6, 2015 /EINPresswire.com/ -- Returning for its 15th year and following on from the major success of previous events, SMi is proud to announce that registration is now live for the Advances and Progress in [Drug Design](#) conference taking place on 15th-16th February 2016 in London, UK.



This year's event will focus on enabling biophysical tools and highlight key advancements in [protein](#)-based [drug discovery](#), with new areas of discussion including: Small molecules in drug design - A look at novel inhibitors and favourable protein-fragment interactions. It will take a closer look at combined HTS and FBDD methods for lead generation and the application of biophysical methods such as: X-Ray Crystallography, NMR, Biocore and ITC to aid the prioritisation of target inhibitors.

“

Returning for its 15th year and following on from the major success of previous events, SMi is proud to announce that registration is now live for the Advances and Progress in Drug Design conference

*SMi Group*

Conference program will include interactive presentations, case studies and keynote addresses which will enable attendees to gain new insights in organised dynamic structures on a 3D project database using novel algorithms to determine specific subunits, as well as understand data mining workflows and the IMI Open PHACTS projects.

Plus, two interactive half-day post-conference workshops will be presented by Barcelona University: A fresh view on molecular recognition: the dynamic perspective and C4X Discovery: Analysis and Application of Ligand Conformation in

Drug Design.

Confirmed Sponsors for 2016: Chemical Computing Group and Openeye Scientific Software

Chair for 2016:

•Gregg Seigal, Chief Executive Officer, ZoBio

Featured Speakers:

•Doug Johnson, Research Fellow, Pfizer

•Tove Sjögren, Associate Director, AstraZeneca

- Herman van Vlijmen, Senior Director, Janssen
- Armin Ruf, Section Head, Biostructure, Roche
- Gianni Chessari, Director, Astex Pharmaceuticals
- Hans Matter, Senior Scientist, Sanofi-Aventis, and many more

Those who are interested in attending are advised to register now to secure the place at the conference and save £400.

For the full event agenda/ to register please visit: [www.drug-desig.co.uk/ein](http://www.drug-desig.co.uk/ein)

----- END -----

About SMi Group:

Established since 1993, the SMi Group is a global event-production company that specializes in Business-to-Business Conferences, Workshops, Masterclasses and online Communities. We create and deliver events in the Defence, Security, Energy, Utilities, Finance and Pharmaceutical industries. We pride ourselves on having access to the world's most forward thinking opinion leaders and visionaries, allowing us to bring our communities together to Learn, Engage, Share and Network. More information can be found at <http://www.smi-online.co.uk>

Anna Serazetdinova  
SMi Group Ltd  
+44 20 7827 6180  
email us here

---

This press release can be viewed online at: <http://www.einpresswire.com>

Disclaimer: If you have any questions regarding information in this press release please contact the company listed in the press release. Please do not contact EIN Presswire. We will be unable to assist you with your inquiry. EIN Presswire disclaims any content contained in these releases.

© 1995-2015 IPD Group, Inc. All Right Reserved.